Louvain-La-Neuve, Belgium, 18 June 2019 - Belfius Insurance, the insurance branch of Belfius Bank and Insurance, and its shareholder the Belgian Société Fédérale de Participations et d’Investissements (SFPI), are pleased to announce today that they now hold more than 3% of the capital of Ion Beam Applications SA (IBA).
This capital participation is in line with Belfius Bank and Insurance’s strategy to be a privileged partner of Belgian companies and support them in the long run.
Frédéric Van der Schueren, Chief Financial Officer of Belfius Insurance, commented: “Our participation in IBA’s equity capital perfectly suits our strategy to support and invest in the Belgian economy, and fits our objective to hold a diversified portfolio. Belfius Insurance is proud to support one of Belgium’s technology champions, which is actively fighting cancer.”
Olivier Legrain, Chief Executive Officer of IBA, added, “It is important to IBA that we can count on Belgian partners who share our values and support us in the long run. This allows us to continue innovating and developing cutting-edge technologies to fight cancer and helps us to keep our position of undisputed market leader in all of our markets. Our trusted and long-standing relationship with Belfius enables us to move forward in order to consolidate and develop our activities”
About Belfius Insurance
Belfius Insurance is a subsidiary of Belfius Bank and Insurance, a bank insurer with solid local roots. The group operates in Belgium in three main areas: retail, commercial and private banking, as well as wealth management, financial services for the public and social sector and for corporate clients (wholesale banking) and insurance (Life and Non-Life Products).
Belfius Bank and Insurance is wholly owned by the Belgian State via the The Federal Holding and Investment Company.
About Société Fédérale de Participations et d’Investissements (SFPI)
The Federal Holding and Investment Company (SFPI-FPIM) centrally manages the federal government’s shareholdings, cooperates with the government on specific projects and pursues its own investment policy in the interests of the Belgian economy.
About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,400 people worldwide, IBA has installed systems across the world.
IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com
For further information, please contact:
IBA
Soumya Chandramouli
Chief Financial Officer
+32 10 475 890
Investorrelations@iba-group.com
Thomas Ralet
Vice-President Corporate Communication
+32 10 475 890
communication@iba-group.com
For media and investor enquiries:
Consilium Strategic Communications
Amber Fennell, Angela Gray, Lizzie Seeley
+44 (0) 20 3709 5700
IBA@consilium-comms.com